Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab

Documenti analoghi

• Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single‐arm, open‐label study
  di: Christian Pfrepper, et al.
  Pubblicazione: (2024)
• Emicizumab plasma levels after accelerated saturation in acquired haemophilia A
  di: Tristan Kloeter, et al.
  Pubblicazione: (2024)
• Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience
  di: Robert Klamroth, et al.
  Pubblicazione: (2024)
• Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real‐world evidence
  di: Gili Kenet, et al.
  Pubblicazione: (2024)
• Postpartum Acquired Hemophilia A in Two Women With Previously Undiagnosed Carrier Status for von Willebrand Disease Type 2N and Heterozygous p.R854Q Mutation
  di: Maria Weise, et al.
  Pubblicazione: (2026)